Kwon Young M
Department of Pharmaceutical Sciences, College of Pharmacy, Health Professions Division, Nova Southeastern University 3200 S. University Dr. Fort Lauderdale, FL 33328.
Bioimpacts. 2021;11(2):85-86. doi: 10.34172/bi.2021.15. Epub 2020 Oct 29.
Although thrombolytic agents have been used for several decades in the treatment of thromboembolic conditions, there is an unmet need for the development of safer thrombolytic agents. The development of new molecules themselves may not be sufficient. This has sparked a growing interest in the design of novel nanoscale drug carrier systems for the delivery of thrombolytic enzymes in an effort to address its fatal side effects. There are numerous proof-of-concept reports on such nanoscale systems that seek to capitalize on the pathophysiologic signatures of thrombosis as well as external biochemical/physical triggers. Although there may be a long road ahead before we have such new nanoscale therapeutics on the bedside, hopes remain high.
尽管溶栓剂已用于治疗血栓栓塞性疾病数十年，但开发更安全的溶栓剂仍存在未满足的需求。新分子本身的开发可能并不足够。这引发了人们对设计新型纳米级药物载体系统以递送溶栓酶的兴趣日益浓厚，旨在解决其致命的副作用。关于此类纳米级系统有许多概念验证报告，这些报告试图利用血栓形成的病理生理特征以及外部生化/物理触发因素。尽管在床边应用此类新型纳米疗法之前可能还有很长的路要走，但人们的希望依然很高。
